Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Nature Medicine · 2025
DOI: 10.1038/s41591-024-03398-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Medicine, 2025. Verfasst von Seong-Keun Yoo und 36 weiteren Autor:innen. Beteiligte Einrichtung: Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy, Hematologic Tests. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Predicting whether a patient with cancer will benefit from immune checkpoint inhibitors (ICIs) without resorting to advanced genomic or immunologic assays is an important clinical need. To address this, we developed and evaluated SCORPIO, a machine learning system that utilizes routine blood tests (complete blood count and comprehensive metabolic profile) alongside clinical characteristics from 9,745 ICI-treated patients across 21 cancer types. SCORPIO was trained on data from 1,628 patients across 17 cancer types from Memorial Sloan Kettering Cancer Center. In two internal test sets comprising 2,511 patients across 19 cancer types, SCORPIO achieved median time-dependent area under the receiver operating characteristic curve (AUC(t)) values of 0.763 and 0.759 for predicting overall survival at 6, 12, 18, 24 and 30 months, outperforming tumor mutational burden (TMB), which showed median AUC(t) values of 0.503 and 0.543. Additionally, SCORPIO demonstrated superior predictive performance for predicting clinical benefit (tumor response or prolonged stability), with AUC values of 0.714 and 0.641, compared to TMB (AUC = 0.546 and 0.573). External validation was performed using 10 global phase 3 trials (4,447 patients across 6 cancer types) and a real-world cohort from the Mount Sinai Health System (1,159 patients across 18 cancer types). In these external cohorts, SCORPIO maintained robust performance in predicting ICI outcomes, surpassing programmed death-ligand 1 immunostaining. These findings underscore SCORPIO's reliability and adaptability, highlighting its potential to predict patient outcomes with ICI therapy across diverse cancer types and healthcare settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Yoo, S. K., Fitzgerald, C. W., Cho, B. A., Fitzgerald, B. G., Han, C., Koh, E. S., Pandey, A., Sfreddo, H., Crowley, F., Korostin, M. R., Debnath, N., Leyfman, Y., Valero, C., Lee, M., Vos, J. L., Lee, A. S., Zhao, K., Lam, S., Olumuyide, E., …, & Chowell, D. (2025). Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nature Medicine. https://doi.org/10.1038/s41591-024-03398-5
Vancouver
Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nature Medicine. 2025. doi:10.1038/s41591-024-03398-5
BibTeX
@article{Yoo2025,
author = {Yoo, Seong-Keun and Fitzgerald, Conall W and Cho, Byuri Angela and Fitzgerald, Bailey G and Han, Catherine and Koh, Elizabeth S and Pandey, Abhinav and Sfreddo, Hannah and Crowley, Fionnuala and Korostin, Michelle Rudshteyn and Debnath, Neha and Leyfman, Yan and Valero, Cristina and Lee, Mark and Vos, Joris L and Lee, Andrew Sangho and Zhao, Karena and Lam, Stanley and Olumuyide, Ezekiel and Kuo, Fengshen and Wilson, Eric A and Hamon, Pauline and Hennequin, Clotilde and Saffern, Miriam and Vuong, Lynda and Hakimi, A Ari and Brown, Brian and Merad, Miriam and Gnjatic, Sacha and Bhardwaj, Nina and Galsky, Matthew D and Schadt, Eric E and Samstein, Robert M and Marron, Thomas U and Gönen, Mithat and Morris, Luc G T and Chowell, Diego},
title = {Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-024-03398-5}
}
EUVIMED